论文部分内容阅读
近年来,左旋咪唑(Levamisole,LMS)作为一种免疫治疗剂被试用于各种癌肿的治疗,其效果各家报告尚不一致。本文报告我院外科1974年1月至1980年3月,用左旋咪唑治疗Ⅱ期乳癌和晚期胃癌的临床及免疫学实验室观察。资料分析一、Ⅱ期乳癌30例 (一) 选择标准符合1959年全国肿癌学术座谈会建议的乳癌分期标准的第Ⅱ期:癌瘤直径不超过5厘米,尚能推动,与复盖的皮肤有粘连,同侧腋窝有数个散在而能推动的淋巴结。
In recent years, levamisole (LMS) as an immunotherapeutic agent was tested for the treatment of various types of cancer, the results of various reports are not consistent. This article reports from January 1974 to March 1980 in our hospital surgery, levamisole treatment of stage Ⅱ breast cancer and advanced gastric cancer clinical and immunological laboratory observations. Data analysis First, 30 cases of stage Ⅱ breast cancer (a) selection criteria in line with the 1959 National Cancer Symposium recommended breast cancer staging criteria of stage Ⅱ: cancer diameter of not more than 5 cm, still able to promote, and cover the skin There are adhesions, ipsilateral axillary lymph nodes scattered in several can promote.